Yew Y.W., Thyssen J.P., Silverberg J.I. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390–401. https://doi.org/10.1016/j.jaad.2018.09.035..
DOI: 10.1016/j.jaad.2018.09.035
Bylund S., Kobyletzki L.B., Svalstedt M., Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. https://doi.org/10.2340/00015555-3510..
DOI: 10.2340/00015555-3510
Sugita K., Akdis C.A. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020;69(2):204–214. https://doi.org/10.1016/j.alit.2019.08.013..
DOI: 10.1016/j.alit.2019.08.013
Hill D.A., Spergel J.M. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. https://doi.org/10.1016/j.anai.2017.10.037..
DOI: 10.1016/j.anai.2017.10.037
Aw M., Penn J., Gauvreau G.M., Lima H., Sehmi R. Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020;181(1):1–10. https://doi.org/10.1159/000502958..
DOI: 10.1159/000502958
Ridolo E., Melli V., De’ Angelis G., Martignago I. Eosinophilic disorders of the gastro-intestinal tract: an update. Clin Mol Allergy. 2016;14:17. https://doi.org/10.1186/s12948-016-0055-y..
DOI: 10.1186/s12948-016-0055-y
Guarino M.P., Cicala M., Behar J. Eosinophilic esophagitis: New insights in pathogenesis and therapy. World J Gastrointest Pharmacol Ther. 2016;7(1):66–77. https://doi.org/10.4292/wjgpt.v7.i1.66..
DOI: 10.4292/wjgpt.v7.i1.66
Hill D.A., Grundmeier R.W., Ramos M., Spergel J.M. Eosinophilic Esophagitis Is a Late Manifestation of the Allergic March. J Allergy Clin Immunol Pract. 2018;6(5):1528–1533. https://doi.org/10.1016/j.jaip.2018.05.010..
DOI: 10.1016/j.jaip.2018.05.010
Yu S.H., Attarian H., Zee P., Silverberg J.I. Burden of Sleep and Fatigue in US Adults With Atopic Dermatitis. Dermatitis. 2016;27(2):50–58. https://doi.org/10.1097/DER.0000000000000161..
DOI: 10.1097/DER.0000000000000161
Yu S.H., Silverberg J.I. Association between Atopic Dermatitis and Depression in US Adults. J Invest Dermatol. 2015;135(12):3183–3186. https://doi.org/10.1038/jid.2015.337..
DOI: 10.1038/jid.2015.337
Chiesa Fuxench Z.C., Block J.K., Boguniewicz M., Boyle J., Fonacier L., Gelfand J.M. et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. J Invest Dermatol. 2019;139(3):583–590. https://doi.org/10.1016/j.jid.2018.08.028..
DOI: 10.1016/j.jid.2018.08.028
Silverberg J.I., Simpson E.L. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107–114. https://doi.org/10.1097/DER.0000000000000034..
DOI: 10.1097/DER.0000000000000034
Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. https://doi.org/10.1111/jdv.14888..
DOI: 10.1111/jdv.14888
Wollenberg A., Oranje A., Deleuran M., Simon D., Szalai Z., Kunz B. et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729–747. https://doi.org/10.1111/jdv.13599..
DOI: 10.1111/jdv.13599
Ungar B., Garcet S., Gonzalez J., Dhingra N., Correa da Rosa J., Shemer A. et al. An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Invest Dermatol. 2017;137(3):603–613. https://doi.org/10.1016/j.jid.2016.09.037..
DOI: 10.1016/j.jid.2016.09.037
Simpson E.L., Bruin-Weller M., Flohr C., Ardern-Jones M.R., Barbarot S., Deleuran M. et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623–633. https://doi.org/10.1016/j.jaad.2017.06.042..
DOI: 10.1016/j.jaad.2017.06.042
Silverberg J.I., Greenland P. Eczema and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol. 2015;135(3):721–728.e6. https://doi.org/10.1016/j.jaci.2014.11.023..
DOI: 10.1016/j.jaci.2014.11.023
Zhang A., Silverberg J.I. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. J Am Acad Dermatol. 2015;72(4):606–616.e4. https://doi.org/10.1016/j.jaad.2014.12.013..
DOI: 10.1016/j.jaad.2014.12.013
Silverberg J.I., Becker L., Kwasny M., Menter A., Cordoro K.M., Paller A.S. Central obesity and high blood pressure in pediatric patients with atopic dermatitis. JAMA Dermatol. 2015;151(2):144–152. https://doi.org/10.1001/jamadermatol.2014.3059..
DOI: 10.1001/jamadermatol.2014.3059
Hjuler K.F., Böttcher M., Vestergaard C., Deleuran M., Raaby L., Bøtker H.E. et al. Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. Am J Med. 2015;128(12):1325–1334.e2. https://doi.org/10.1016/j.amjmed.2015.05.041..
DOI: 10.1016/j.amjmed.2015.05.041
Кубанов А.А., Намазова-Баранова Л.С., Хаитов Р.М., Ильина Н.И., Алексеева Е.А., Амбарчян Э.Т. и др. Атопический дерматит: клинические рекомендации. М.; 2021. 81 c. Режим доступа: https://cr.minzdrav.gov.ru/schema/265_2.https://cr.minzdrav.gov.ru/schema/265_2
Кубанов А.А., Намазова-Баранова Л.С., Хаитов Р.М., Ильина Н.И., Алексеева Е.А., Амбарчян Э.Т. и др. Атопический дерматит: клинические рекомендации. М.; 2021. 81 c. Режим доступа: https://cr.minzdrav.gov.ru/schema/265_2.https://cr.minzdrav.gov.ru/schema/265_2
Brunner P.M., Guttman-Yassky E., Leung D.Y. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76. https://doi.org/10.1016/j.jaci.2017.01.011..
DOI: 10.1016/j.jaci.2017.01.011
Johnson B.B., Franco A.I., Beck L.A., Prezzano J.C. Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181–192. https://doi.org/10.2147/CCID.S163814..
DOI: 10.2147/CCID.S163814
Guttman-Yassky E., Krueger J.G. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68–73. https://doi.org/10.1016/j.coi.2017.08.008..
DOI: 10.1016/j.coi.2017.08.008
Furue M., Tsuji G., Mitoma C., Nakahara T., Chiba T., Morino-Koga S., Uchi H. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci. 2015;80(2):83–88. https://doi.org/10.1016/j.jdermsci.2015.07.011..
DOI: 10.1016/j.jdermsci.2015.07.011
Gutowska-Owsiak D., Schaupp A.L., Salimi M., Selvakumar T.A., McPherson T., Taylor S., Ogg G.S. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21(2):104–110. https://doi.org/10.1111/j.1600-0625.2011.01412.x..
DOI: 10.1111/j.1600-0625.2011.01412.x
Bin L., Leung D.Y. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin Immunol. 2016;12:52. https://doi.org/10.1186/s13223-016-0158-5..
DOI: 10.1186/s13223-016-0158-5
Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. https://doi.org/10.1038/ng1767..
DOI: 10.1038/ng1767
Brown S.J., Kroboth K., Sandilands A., Campbell L.E., Pohler E., Kezic S. et al. Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. J Invest Dermatol. 2012;132(1):98–104. https://doi.org/10.1038/jid.2011.342..
DOI: 10.1038/jid.2011.342
Irvine A.D., McLean W.H., Leung D.Y. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315–1327. https://doi.org/10.1056/NEJMra1011040..
DOI: 10.1056/NEJMra1011040
Howell M.D., Kim B.E., Gao P., Grant A.V., Boguniewicz M., Debenedetto A. et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150–155. https://doi.org/10.1016/j.jaci.2007.04.031..
DOI: 10.1016/j.jaci.2007.04.031
Gutowska-Owsiak D., Schaupp A.L., Salimi M., Taylor S., Ogg G.S. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol. 2011;165(3):492–498. https://doi.org/10.1111/j.1365-2133.2011.10400.x..
DOI: 10.1111/j.1365-2133.2011.10400.x
Takei K., Mitoma C., Hashimoto-Hachiya A., Uchi H., Takahara M., Tsuji G. et al. Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor. J Dermatol. 2015;42(2):171–180. https://doi.org/10.1111/1346-8138.12717..
DOI: 10.1111/1346-8138.12717
Gandhi N.A., Bennett B.L., Graham N.M., Pirozzi G., Stahl N., Yancopoulos G.D. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. https://doi.org/10.1038/nrd4624..
DOI: 10.1038/nrd4624
Gandhi N.A., Pirozzi G., Graham N.M.H. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. https://doi.org/10.1080/1744666X.2017.1298443..
DOI: 10.1080/1744666X.2017.1298443
Furue M., Chiba T., Tsuji G., Ulzii D., Kido-Nakahara M., Nakahara T., Kadono T. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. https://doi.org/10.1016/j.alit.2016.12.002..
DOI: 10.1016/j.alit.2016.12.002
Saunders S.P., Moran T., Floudas A., Wurlod F., Kaszlikowska A., Salimi M. et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J Allergy Clin Immunol. 2016;137(2):482–491. https://doi.org/10.1016/j.jaci.2015.06.045..
DOI: 10.1016/j.jaci.2015.06.045
Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res. 2013;351(2):289–300. https://doi.org/10.1007/s00441-013-1558-1..
DOI: 10.1007/s00441-013-1558-1
Furio L., de Veer S., Jaillet M., Briot A., Robin A., Deraison C., Hovnanian A. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J Exp Med. 2014;211(3):499–513. https://doi.org/10.1084/jem.20131797..
DOI: 10.1084/jem.20131797
Bao K., Reinhardt R.L. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine. 2015;75(1):25–37. https://doi.org/10.1016/j.cyto.2015.05.008..
DOI: 10.1016/j.cyto.2015.05.008
He C.H., Lee C.G., Dela Cruz C.S., Lee C.M., Zhou Y., Ahangari F. et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4(4):830–841. https://doi.org/10.1016/j.celrep.2013.07.032..
DOI: 10.1016/j.celrep.2013.07.032
Oh M.H., Oh S.Y., Yu J., Myers A.C., Leonard W.J., Liu Y.J. et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol. 2011;186(12):7232–7242. https://doi.org/10.4049/jimmunol.1100504..
DOI: 10.4049/jimmunol.1100504
McCormick S.M., Heller N.M. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75(1):38–50. https://doi.org/10.1016/j.cyto.2015.05.023..
DOI: 10.1016/j.cyto.2015.05.023
Klasa B., Cichocka-Jarosz E. Atopic Dermatitis – Current State of Research on Biological Treatment. J Mother Child. 2020;24(1):53–66. https://doi.org/10.34763/jmotherandchild.2020241.2003.0000010..
DOI: 10.34763/jmotherandchild.2020241.2003.0000010
Noda S., Suárez-Fariñas M., Ungar B., Kim S.J., de Guzman Strong C., Xu H. et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264. https://doi.org/10.1016/j.jaci.2015.08.015..
DOI: 10.1016/j.jaci.2015.08.015
Suárez-Fariñas M., Dhingra N., Gittler J., Shemer A., Cardinale I., de Guzman Strong C. et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361–370. https://doi.org/10.1016/j.jaci.2013.04.046..
DOI: 10.1016/j.jaci.2013.04.046
Renert-Yuval Y., Guttman-Yassky E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. Ann Allergy Asthma Immunol. 2020;124(1):28–35. https://doi.org/10.1016/j.anai.2019.10.005..
DOI: 10.1016/j.anai.2019.10.005
Martel B.C., Litman T., Hald A., Norsgaard H., Lovato P., Dyring-Andersen B. et al. Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis. Exp Dermatol. 2016;25(6):453–459. https://doi.org/10.1111/exd.12967..
DOI: 10.1111/exd.12967
Esaki H., Brunner P.M., Renert-Yuval Y., Czarnowicki T., Huynh T., Tran G. et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651. https://doi.org/10.1016/j.jaci.2016.07.013..
DOI: 10.1016/j.jaci.2016.07.013
Kim J., Kim B.E., Lee J., Han Y., Jun H.Y., Kim H. et al. Epidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy. J Allergy Clin Immunol. 2016;137(4):1282–1285.e4. https://doi.org/10.1016/j.jaci.2015.12.1306..
DOI: 10.1016/j.jaci.2015.12.1306
Renert-Yuval Y., Guttman-Yassky E. Systemic therapies in atopic dermatitis: The pipeline. Clin Dermatol. 2017;35(4):387–397. https://doi.org/10.1016/j.clindermatol.2017.03.012..
DOI: 10.1016/j.clindermatol.2017.03.012
Noda S., Krueger J.G., Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–336. https://doi.org/10.1016/j.jaci.2014.11.015..
DOI: 10.1016/j.jaci.2014.11.015
Moyle M., Cevikbas F., Harden J.L., Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019;28(7):756–768. https://doi.org/10.1111/exd.13911..
DOI: 10.1111/exd.13911
Czarnowicki T., Krueger J.G., Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734. https://doi.org/10.1016/j.jaci.2017.04.004..
DOI: 10.1016/j.jaci.2017.04.004
Harb H., Chatila T.A. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5–14. https://doi.org/10.1111/cea.13491..
DOI: 10.1111/cea.13491
Massoud A.H., Charbonnier L.M., Lopez D., Pellegrini M., Phipatanakul W., Chatila T.A. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nat Med. 2016;22(9):1013–1022. https://doi.org/10.1038/nm.4147..
DOI: 10.1038/nm.4147
Thaçi D., Simpson E.L., Beck L.A., Bieber T., Blauvelt A., Papp K. et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebocontrolled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52. https://doi.org/10.1016/S0140-6736(15)00388-8..
DOI: 10.1016/S0140-6736(15)00388-8
Simpson E.L., Bieber T., Guttman-Yassky E., Beck L.A., Blauvelt A., Cork M.J. et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335–2348. https://doi.org/10.1056/NEJMoa1610020..
DOI: 10.1056/NEJMoa1610020
Deleuran M., Thaçi D., Beck L.A., de Bruin-Weller M., Blauvelt A., Forman S. et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. https://doi.org/10.1016/j.jaad.2019.07.074..
DOI: 10.1016/j.jaad.2019.07.074
Blauvelt A., de Bruin-Weller M., Gooderham M., Cather J.C., Weisman J., Pariser D. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. https://doi.org/10.1016/S0140-6736(17)31191-1..
DOI: 10.1016/S0140-6736(17)31191-1
De Bruin-Weller M., Thaçi D., Smith C.H., Reich K., Cork M.J., Radin A. et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. https://doi.org/10.1111/bjd.16156..
DOI: 10.1111/bjd.16156
Gooderham M.J., Hong H.C., Eshtiaghi P., Papp K.A. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28–S36. https://doi.org/10.1016/j.jaad.2017.12.022..
DOI: 10.1016/j.jaad.2017.12.022
Simpson E.L., Paller A.S., Siegfried E.C., Boguniewicz M., Sher L., Gooderham M.J. et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56. https://doi.org/10.1001/jamadermatol.2019.3336..
DOI: 10.1001/jamadermatol.2019.3336
Paller A.S., Bansal A., Simpson E.L., Boguniewicz M., Blauvelt A., Siegfried E.C. et al. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020;21(1):119–131. https://doi.org/10.1007/s40257-019-00478-y..
DOI: 10.1007/s40257-019-00478-y
Paller A.S., Siegfried E.C., Thaçi D., Wollenberg A., Cork M.J., Arkwright P.D. et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. https://doi.org/10.1016/j.jaad.2020.06.054..
DOI: 10.1016/j.jaad.2020.06.054
Abraham S., Haufe E., Harder I., Heratizadeh A., Kleinheinz A., Wollenberg A. et al. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany. Br J Dermatol. 2020;183(2):382–384. https://doi.org/10.1111/bjd.18958..
DOI: 10.1111/bjd.18958
Ruiz-Villaverde R., Dominguez-Cruz J., Armario-Hita J.C., Martinez-Pilar L., Alcantara-Luna S., Pereyra-Rodriguez J.J. Dupilumab: short-term effectiveness and security in real clinical practice – A retrospective multicentric study. J Eur Acad Dermatol Venereol. 2019;33(1):e21–e22. https://doi.org/10.1111/jdv.15118..
DOI: 10.1111/jdv.15118
Carugno A., Raponi F., Locatelli A.G., Vezzoli P., Gambini D.M., Di Mercurio M. et al. No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area – Bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol. 2020;34(9):e433–e434. https://doi.org/10.1111/jdv.16552..
DOI: 10.1111/jdv.16552
Ceryn J., Niedźwiedź M., Skibińska M., Ciążyńska M., Lesiak A., Narbutt J. COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review. Clin Cosmet Investig Dermatol. 2021;14:1131–1138. https://doi.org/10.2147/CCID.S321003..
DOI: 10.2147/CCID.S321003
Kridin K., Schonmann Y., Solomon A., Onn E., Bitan D.T., Weinstein O., Cohen A.D. Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study. Immunol Res. 2022;70(1):106–113. https://doi.org/10.1007/s12026-021-09234-z..
DOI: 10.1007/s12026-021-09234-z
Hamilton J.D., Suárez-Fariñas M., Dhingra N., Cardinale I., Li X., Kostic A. et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300. https://doi.org/10.1016/j.jaci.2014.10.013..
DOI: 10.1016/j.jaci.2014.10.013
Weidinger S., Beck L.A., Bieber T., Kabashima K., Irvine A.D. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. https://doi.org/10.1038/s41572-018-0001-z..
DOI: 10.1038/s41572-018-0001-z